Mara Goldstein
Stock Analyst at Mizuho
(2.84)
# 1,851
Out of 5,012 analysts
77
Total ratings
44.83%
Success rate
9.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $9.43 | +218.13% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.18 | +358.72% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $9.00 | -11.11% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $14.03 | +199.36% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $12.03 | +315.63% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $16.45 | +173.56% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $87.17 | -11.67% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $2.48 | +182.26% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.39 | +475.54% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.63 | +1,815.71% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $58.00 | +55.17% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $6.87 | -49.05% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.46 | +14,534.15% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.11 | +227.33% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $87.61 | +48.38% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $3.33 | -39.94% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.49 | +705.37% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.14 | +6,393.51% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $60.17 | -66.76% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $8.72 | +450.46% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.23 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.17 | +170.79% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $9.43
Upside: +218.13%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.18
Upside: +358.72%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $9.00
Upside: -11.11%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $14.03
Upside: +199.36%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $12.03
Upside: +315.63%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $16.45
Upside: +173.56%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $87.17
Upside: -11.67%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $2.48
Upside: +182.26%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.39
Upside: +475.54%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.63
Upside: +1,815.71%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $58.00
Upside: +55.17%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $6.87
Upside: -49.05%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.46
Upside: +14,534.15%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.11
Upside: +227.33%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $87.61
Upside: +48.38%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $3.33
Upside: -39.94%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.49
Upside: +705.37%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.14
Upside: +6,393.51%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $60.17
Upside: -66.76%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $8.72
Upside: +450.46%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $26.23
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.17
Upside: +170.79%